Thrombopoietic compounds

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S192100, C530S350000

Reexamination Certificate

active

07981425

ABSTRACT:
The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3941763 (1976-03-01), Sarantakis
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4289872 (1981-09-01), Denkewalter et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5229490 (1993-07-01), Tam
patent: 5284656 (1994-02-01), Platz et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5733731 (1998-03-01), Schatz et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5869451 (1999-02-01), Dover et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6835809 (2004-12-01), Liu et al.
patent: 6919426 (2005-07-01), Boone et al.
patent: 7442778 (2008-10-01), Gegg et al.
patent: 2003/0176352 (2003-09-01), Min et al.
patent: 2003/0195156 (2003-10-01), Min et al.
patent: 2003/0229023 (2003-12-01), Oliner et al.
patent: 2003/0236193 (2003-12-01), Oliner et al.
patent: 2004/0087778 (2004-05-01), Feige et al.
patent: 2006/0140934 (2006-06-01), Gegg et al.
patent: 2009/0012272 (2009-01-01), Gegg et al.
patent: 2009/0022744 (2009-01-01), Gegg et al.
patent: 2009/0041768 (2009-02-01), Gegg et al.
patent: 2009/0234104 (2009-09-01), Gegg et al.
patent: 2009/0281286 (2009-11-01), Gregg et al.
patent: 2009/0286964 (2009-11-01), Gegg et al.
patent: 991 1996 (1997-06-01), None
patent: 2697 1997 (1998-08-01), None
patent: 2201 2004 (2006-04-01), None
patent: 284 2007 (2007-12-01), None
patent: 0 315 456 (1989-05-01), None
patent: WO 90/04606 (1990-05-01), None
patent: WO 93/21259 (1993-10-01), None
patent: WO 95/18858 (1995-07-01), None
patent: WO 95/21919 (1995-08-01), None
patent: WO 95/21920 (1995-08-01), None
patent: WO 95/26746 (1995-10-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 96/40987 (1996-12-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 00/24770 (2000-05-01), None
patent: WO 03/057134 (2003-07-01), None
patent: WO 2004/026329 (2004-04-01), None
patent: WO 2005/023834 (2005-03-01), None
patent: WO 2006/010057 (2006-01-01), None
patent: WO 2007/022070 (2007-02-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Abuchowski et al., “Soluble Polymer-Enzyme Adducts”, Enzymes as Drugs, Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, 367-383 (1981).
Adjei et al., “Bioavailability of Leuprolide Following Intratracheal Administration of Beagle Dogs”, Internatl. J. Pharmaceutics, 61:135-144 (1990).
Adjei et al., “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers”, Pharma. Res., 7(6):565-569 (1990).
Alberts et al., “Synthesis of a Novel Hematopoietic Peptide, SK&F 107647”, Thirteenth Am. Pep. Symp., 367-369 (1993).
Alexander et al., “Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl”, Blood 87(6):2162-2170 (1996).
Bartley et al., “Identification and Cloning of a Megakaryocyte Growth and Development Factor That Is a Ligand for the Cytokine Receptor Mpl”, Cell 77:1117-1124 (1994).
Basser et al., “Thrombopoietic Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (Peg-rHuMGDF) in Patients with Advanced Cancer”, The Lancet 348:1279-1281 (1996).
Bhatnagar et al., Structure-Activity Relationships of Novel Hemtoregulatory Peptides, J. Med. Chem., 39:3814-3819 (1996).
Braquet et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig”, J. Cardiovasc. Pharmacol., 13 (suppl. 5): 143-146 (1989).
Capon et al.,“Designing CD4 Immunoadhesins for AIDS Therapy,” Nature, 337:525-531 (1989).
Chang et al., “Cloning and Characterization of the Human Megakaryocyte Growth and Development Factor (MGDF) Gene”, Journal of Biological Chemistry 270:511-514 (1995).
Choi et al., “Platelets Generated in Vitro From Proplatelet-Displaying Human Megakaryocytes Are Functional”, Blood 85:402-413 (1995).
Clackson et al., “A Hot Spot of Binding Energy in a Hormone-Receptor Interface,” Science, 267: 383-386 (1995).
Cortese et al., “Selection of Biologically Active Peptides by Phage Display of Random Peptide Libraries,” Curr. Opin. Biotech., 7:616-621 (1996).
Creighton, T.E., Proteins: Structure and Molecule Principles, W.H. Freeman & Co., New York, 79-86 (1983).
Cwirla et al., “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine,” Science, 276:1696-1699 (1997).
Davis et al., “Preparation and Characterization of Antibodies with Specificity for the Amino-Terminal Tetrapeptide Sequence of the Platelet-Derived Connective Tissue,” Biochem. Intl., 10(3):395-404 (1985).
de Sauvage et al., “Stimulation of Megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand”, Nature 369:533-538 (1994).
Debili et al., “The Mpl Receptor Is Expressed in the Megakaryocytic Lineage From Late Progenitors to Platelets”, Blood 85:391-401 (1995).
Debs et al., “Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats” J. Immunol. 140:3482-3488 (1988).
Dedman et al., “Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides,” J. Biol. Chem., 268(31): 23025-23030 (1993).
Delgado et al., “Coupling of PEG to Protein by Activation With Tresyl Chloride, Applications in Immunoaffinity Cell Partitioning,” Fisher et al., eds., Separations Using Aqueous Phase Systems, Applications in Cell Biology and Biotechnology, Plenum Press, N. Y. N. Y., 211-213 (1989).
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,” Science, 249:404-406 (1990).
Ellison et al., “The Nucleotide Sequence of a Human Immunoglobulin Cy1gene,” Nucleic Acids Res., 10(13): 4071-4079 (1982).
Erickson et al., “Solid-Phase Peptide Synthesis,” The Proteins, 3rd Ed., 2:255-517 (1976).
Finn et al., “The Synthesis of Peptides by Solution Methods with Emphasis on Peptide Hormones,” The Proteins, 3rd Ed., 2:105-253 (1976).
Fisher et al., “Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein”, N. Engl. J. Med. 334(26):1697-1702 (1996).
Francis et al., “PEG-Modified Proteins,” Stability of protein pharmaceuticals: Part B in vivo pathways of degradation and strategies for protein stabilization, Eds. Ahern., T. Manning, M.C., Plenum, N.Y., pp. 235-263 (1991).
Francis, Gillian E., “Protein Modification and Fusion Proteins”, Focus on Growth Factors, 3:4-11 (1992).
Gurney et al., “Genomic Structure, Chromosomal Localization, and Conserved Alternative Splice Forms of Thrombopoietin”, Blood 85(4):981-988 (1995).
Harvill et al.,

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Thrombopoietic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thrombopoietic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombopoietic compounds will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2702282

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.